Farewell to Chris Richardson

Chris Richardson joined the lab as a Postdoctoral Fellow in July 2014 and made huge advances in human gene editing. He developed new ways to improve NHEJ and HDR, plus discovered out that genome editing in human cells works via the Fanconi Anemia Pathway. Three major first author papers in three years – not bad! Chris will be joining Spotlight Therapeutics as a Group Leader, and may have some additional career news to share soon. We wish you success in all your future endeavors!

SUBMIT A COMMENT

Your email address will not be published.

Filters

Latest News

November 1, 2022

Welcome to David

David received his PhD in Biochemistry from the University of Cambridge in 2022 under the supervision of Prof. Steve Jackson. His work focused on identifying...

October 4, 2022

Welcome to Jan

Jan received his Master´s degree in Immunology from Charles University in 2022, working with Dr. Petr Kašpárek on the role of TNFR1 signalling in the Netherton...

October 4, 2022

Welcome to Ana

Ana received her PhD in Cancer Biology at the University of Zurich, Switzerland. She carried out her pre-and postdoctoral research studies at the Balgrist...

News Archive

Tweets